222 related articles for article (PubMed ID: 37536940)
1. Adjuvant dendritic cell-based immunotherapy after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with malignant peritoneal mesothelioma: a phase II clinical trial.
Dietz MV; Quintelier KLA; van Kooten JP; de Boer NL; Vink M; Brandt-Kerkhof ARM; Verhoef C; Saeys Y; Aerts JGJV; Willemsen M; Van Gassen S; Madsen EVE
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37536940
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial.
de Boer NL; van Kooten JP; Burger JWA; Verhoef C; Aerts JGJV; Madsen EVE
BMJ Open; 2019 May; 9(5):e026779. PubMed ID: 31092657
[TBL] [Abstract][Full Text] [Related]
3. Phase II Trial of Adjuvant Dendritic Cell Vaccine in Combination with Celecoxib, Interferon-α, and Rintatolimod in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastases.
Ramanathan R; Choudry H; Jones H; Girgis M; Gooding W; Kalinski P; Bartlett DL
Ann Surg Oncol; 2021 Aug; 28(8):4637-4646. PubMed ID: 33400000
[TBL] [Abstract][Full Text] [Related]
4. Cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma: Canadian practices and outcomes.
Deban M; Taqi K; Knapp GC; Soucisse M; Curry M; Sidéris L; Dubé P; Khaldi MA; Jedrzejko N; Porter G; Giacomantonio C; Hamilton T; MacNeill A; Mack L; Bouchard-Fortier A
J Surg Oncol; 2023 Sep; 128(4):595-603. PubMed ID: 37249154
[TBL] [Abstract][Full Text] [Related]
5. Ten-year single-center experience with treatment of primary diffuse malignant peritoneal mesothelioma (DMPM) by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
Acs M; Gerken M; Gajic I; Mayr M; Zustin J; Piso P
Langenbecks Arch Surg; 2022 Nov; 407(7):3057-3067. PubMed ID: 35732846
[TBL] [Abstract][Full Text] [Related]
6. Repeat cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent diffuse malignant peritoneal mesothelioma.
Huang Y; Alzahrani NA; Liauw W; Morris DL
Eur J Surg Oncol; 2015 Oct; 41(10):1373-8. PubMed ID: 26227745
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
[No Abstract] [Full Text] [Related]
8. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for malignant peritoneal mesothelioma.
Klos D; Hanuliak J; Lemstrova R; Mohelnikova-Duchonova B; Zapletalova J; Melichar B; Risko J
Bratisl Lek Listy; 2023; 124(5):345-350. PubMed ID: 36876363
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Survival in Patients Treated with Cytoreduction and Heated Intraperitoneal Chemotherapy for Peritoneal Mesothelioma at a Single High-Volume Center.
Valenzuela CD; Solsky IB; Erali RA; Forsythe SD; Mangieri CW; Mainali BB; Russell G; Perry KC; Votanopoulos KI; Shen P; Levine EA
Ann Surg Oncol; 2023 May; 30(5):2666-2675. PubMed ID: 36754945
[TBL] [Abstract][Full Text] [Related]
10. Establishment of a Bayesian network model to predict the survival of malignant peritoneal mesothelioma patients after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy.
Su YD; Zhao X; Ma R; Fu YB; Yang ZR; Wu HL; Yu Y; Yang R; Liang XL; Du XM; Chen Y; Li Y
Int J Hyperthermia; 2023; 40(1):2223374. PubMed ID: 37348853
[TBL] [Abstract][Full Text] [Related]
11. Early recurrence after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
Tan GHC; Chia CS; Tan SH; Soo KC; Teo MCC
Int J Clin Oncol; 2018 Oct; 23(5):989-998. PubMed ID: 29869757
[TBL] [Abstract][Full Text] [Related]
12. Impact of Perioperative Systemic Chemotherapy on Survival for Patients Who have Diffuse Malignant Peritoneal Mesothelioma Treated with CRS-HIPEC.
Chatterjee A; Kusamura S; Baratti D; Guaglio M; Battaglia L; Deraco M
Ann Surg Oncol; 2024 Jan; 31(1):556-566. PubMed ID: 37940804
[TBL] [Abstract][Full Text] [Related]
13. Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a systematic review.
Auer RC; Sivajohanathan D; Biagi J; Conner J; Kennedy E; May T
Eur J Cancer; 2020 Mar; 127():76-95. PubMed ID: 31986452
[TBL] [Abstract][Full Text] [Related]
14. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin in pediatric patients with peritoneal mesothelioma: a single institution experience and long term follow up.
Malekzadeh P; Good M; Hughes MS
Int J Hyperthermia; 2021; 38(1):326-331. PubMed ID: 34139940
[TBL] [Abstract][Full Text] [Related]
15. Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent or progressive diffuse malignant peritoneal mesothelioma: clinicopathologic characteristics and survival outcome.
Ihemelandu C; Bijelic L; Sugarbaker PH
Ann Surg Oncol; 2015 May; 22(5):1680-5. PubMed ID: 25120250
[TBL] [Abstract][Full Text] [Related]
16. A comprehensive review of childbearing after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Papageorgiou D; Manatakis DK; Papakonstantinou K; Kyriazanos ID
Arch Gynecol Obstet; 2020 Oct; 302(4):793-799. PubMed ID: 32653946
[TBL] [Abstract][Full Text] [Related]
17. Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC).
Baratti D; Kusamura S; Cabras AD; Bertulli R; Hutanu I; Deraco M
Eur J Cancer; 2013 Oct; 49(15):3140-8. PubMed ID: 23831335
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma and predictors of survival.
Gilani SNS; Mehta A; Garcia-Fadrique A; Rowaiye B; Jenei V; Dayal S; Chandrakumaran K; Carr N; Mohamed F; Cecil T; Moran B
Int J Hyperthermia; 2018 Aug; 34(5):578-584. PubMed ID: 29431036
[TBL] [Abstract][Full Text] [Related]
19. Diffuse malignant peritoneal mesothelioma: Evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: Multi-Institutional Retrospective Study.
Kepenekian V; Elias D; Passot G; Mery E; Goere D; Delroeux D; Quenet F; Ferron G; Pezet D; Guilloit JM; Meeus P; Pocard M; Bereder JM; Abboud K; Arvieux C; Brigand C; Marchal F; Classe JM; Lorimier G; De Chaisemartin C; Guyon F; Mariani P; Ortega-Deballon P; Isaac S; Maurice C; Gilly FN; Glehen O;
Eur J Cancer; 2016 Sep; 65():69-79. PubMed ID: 27472649
[TBL] [Abstract][Full Text] [Related]
20. Key factors for successful cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat diffuse malignant peritoneal mesothelioma: results from specialized peritoneal cancer center in China.
Su YD; Yang ZR; Li XB; Yu Y; Du XM; Li Y
Int J Hyperthermia; 2022; 39(1):706-712. PubMed ID: 35485308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
